These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22041307)

  • 21. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum ferritin and stool occult blood and colon cancer screening.
    Griffiths EK; Schapira DV
    Cancer Detect Prev; 1991; 15(4):303-5. PubMed ID: 1794137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
    Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Lieberman N; Klang S; Niv Y
    Am J Gastroenterol; 2009 Apr; 104(4):933-8. PubMed ID: 19293792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal occult blood testing for colorectal cancer screening: use the finger.
    Burke CA; Tadikonda L; Machicao V
    Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
    Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Sakaguchi K; Shiratori Y
    Am J Gastroenterol; 2007 Oct; 102(10):2259-64. PubMed ID: 17617203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluating colorectal cancer screening strategies (immunological test vs biochemical test) in Catalonia, Spain 2008-2010].
    García Martínez M; Binefa Rodríguez G; Milà Díaz N; Rodríguez Moranta F; Gonzalo Diego N; Muñoz Sánchez C; Espinàs Piñol JA; Borràs Andrés JM; Moreno Aguado V
    Rev Esp Salud Publica; 2011 Dec; 85(6):593-602. PubMed ID: 22249590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of colorectal diseases in immunological fecal occult blood test (I-FOBT) positive patients in a tertiary care hospital in Bangladesh.
    Mollick SH; Roy PK; Bhuiyan MR; Mia AR; Alam MS; Mollick KA; Pervin S; Hassan MQ
    Mymensingh Med J; 2014 Oct; 23(4):764-9. PubMed ID: 25481598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the occult blood test in screening for colorectal neoplasms. A prospective study using flexible endoscopy.
    Reilly JM; Ballantyne GH; Fleming FX; Zucker KA; Modlin IM
    Am Surg; 1990 Mar; 56(3):119-23. PubMed ID: 2316930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy?
    Choi JS; Choi JY; Cho HG; Han KJ; Kim HM; Cho JH; Kim YJ
    Scand J Gastroenterol; 2013 Jun; 48(6):657-62. PubMed ID: 23713803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic significance of immunohistochemical fecal occult blood test in subjects receiving bidirectional endoscopy.
    Liu HH; Huang TW; Chen HL; Wang TH; Lin JT
    Hepatogastroenterology; 2003; 50(53):1390-2. PubMed ID: 14571744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
    Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
    Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history.
    Rex DK; Lehman GA; Ulbright TM; Smith JJ; Pound DC; Hawes RH; Helper DJ; Wiersema MJ; Langefeld CD; Li W
    Am J Gastroenterol; 1993 Jun; 88(6):825-31. PubMed ID: 8503374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.